Metastatic colorectal cancer patients (stage IV) are encouraged to have biomarker testing done on their tumors. This helps patients and doctors establish treatment plans. Certain drugs have shown to be ineffective if certain mutations (such as KRAS) are present. In this webinar, Dr. Cathy Eng from MD Anderson Cancer Center discusses some of the common biomarker tests, the difference a prognostic test vs. a predictive test and current studies out there involving biomarker mutations, all working to advance the field of medicine.
The content of this video was medically-reviewed. All content written, edited and produced by Fight Colorectal Cancer. This webinar was made possible thanks to the generous support of Amgen Oncology.
For more information, visit FightColorectalCancer.org.